Q1 2018 EPS Estimates for Eagle Pharmaceuticals Lowered by Analyst (EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) – Equities researchers at William Blair cut their Q1 2018 earnings estimates for shares of Eagle Pharmaceuticals in a research report issued on Monday, April 16th. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will earn $0.33 per share for the quarter, down from their prior estimate of $0.81. William Blair also issued estimates for Eagle Pharmaceuticals’ Q3 2018 earnings at $0.59 EPS and Q4 2018 earnings at $0.76 EPS.

How to Become a New Pot Stock Millionaire

A number of other research firms also recently issued reports on EGRX. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 1st. Royal Bank of Canada set a $71.00 target price on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, February 26th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. BidaskClub downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Mizuho reissued an “underperform” rating and set a $40.00 target price (up previously from $37.00) on shares of Eagle Pharmaceuticals in a research report on Wednesday, March 21st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Eagle Pharmaceuticals has an average rating of “Hold” and an average target price of $63.33.

NASDAQ:EGRX opened at $55.16 on Wednesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.88 and a current ratio of 3.99. Eagle Pharmaceuticals has a 1 year low of $45.05 and a 1 year high of $97.15. The company has a market capitalization of $798.98, a price-to-earnings ratio of 16.37 and a beta of 1.38.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.00 by ($0.16). Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The firm had revenue of $46.80 million during the quarter, compared to the consensus estimate of $53.65 million. During the same period in the previous year, the firm earned $3.52 EPS. The business’s revenue was down 42.3% compared to the same quarter last year.

In related news, Director Sander A. Flaum sold 2,340 shares of the business’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 19.50% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Smith Asset Management Group LP acquired a new position in Eagle Pharmaceuticals during the 4th quarter valued at about $187,000. Schroder Investment Management Group acquired a new stake in Eagle Pharmaceuticals during the third quarter worth about $219,000. Campbell Newman Asset Management Inc. acquired a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $200,000. MetLife Investment Advisors LLC acquired a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $218,000. Finally, SG Americas Securities LLC grew its holdings in Eagle Pharmaceuticals by 60.8% during the third quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock worth $269,000 after acquiring an additional 1,706 shares during the period.

COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/20/q1-2018-eps-estimates-for-eagle-pharmaceuticals-lowered-by-analyst-egrx.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply